Bluejay Diagnostics, Inc. 8-K

What Happened
Bluejay Diagnostics, Inc. (NASDAQ: BJDX) filed a Form 8-K on December 30, 2025 (Item 7.01) to disclose a press release issued December 29, 2025 that provides an update on the status of its commercial-scale IL-6 antibody production. The press release is furnished as Exhibit 99.1 to the 8-K.

Key Details

• Filing: Form 8-K filed December 30, 2025 under Item 7.01 (Regulation FD Disclosure).
• Press release date: December 29, 2025; furnished as Exhibit 99.1.
• Topic: Status update regarding commercial-scale production of the company’s IL-6 antibody.
• Exhibits: The 8-K also includes the Inline XBRL cover page (Item 9.01(d), Exhibit 104).

Why It Matters
This 8-K gives investors a formal, public update about Bluejay’s progress on scaling manufacturing for its IL-6 antibody — an operational development that relates to the company’s ability to produce the candidate at commercial scale. Investors should read the furnished press release (Exhibit 99.1) for details on timing, capacity, or next steps, since the 8-K itself only references and furnishes that disclosure under Regulation FD.